FeesSafety
Pluang+

Securities lawsuit filed against Skechers over alleged stock price manipulation during 2025 buyout period

Market News
04 Nov 2026, 16:00 WIB
GlobeNewsWire
View Source
Bearish
Securities lawsuit filed against Skechers over alleged stock price manipulation during 2025 buyout period

A securities class action lawsuit has been filed against Skechers USA, Inc. for allegedly manipulating financial projections and misleading investors during the period from April 24 to September 12, 2025. The complaint claims Skechers withdrew its 2025 financial guidance under false pretenses to depress its stock price and align with 3G Capital Partners' buyout offer, while insiders secured more lucrative terms. Investors who suffered losses during this period can join the lawsuit and seek lead plaintiff status by December 21, 2026. The case highlights potential corporate wrongdoing affecting shareholder value amid a take-private transaction.

Skechers USA, Inc. is the subject of a shareholder alert. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 04, 2026 21:12 WIB: Out of 134 priced US stocks, 119 rose and 12 fell. Notable movers include LEN at USD 89.68 with a 4.17% increase and 100% buy order activity, ZGN at USD 13.33 down 4.17%, and HD at USD 347.56 up 4.17% with 65% sell order activity.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App